Clinical and Economic Burden of First-Line Chemoimmunotherapy for CLL/SLL
Dec 19, 2023
Between high-risk and nonhigh-risk patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) initiating first-line chemoimmunotherapy, high-risk patients experience greater risk of next treatment or death, treatment failure, and higher costs, according to a real-world study presented at the 2021 ASCO Annual Meeting. The economic burden for patients with CLL or SLL who have high-risk genetic abnormalities, often leading to inferior responses to chemoimmunotherapy, is uncertain. “This study aimed to compare real world clinical and economic outcomes in high-risk and perceived nonhigh-risk patients initiating [first-line] chemoimmunotherapy” wrote Lori Leslie, MD, John Theurer Cancer Center, Hackensack, NJ, and colleagues.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…